Early-Stage Biotech, Devices & Diagnostics
We help early-stage innovators, universities, and startups navigate the complex journey from bench to bedside with expert regulatory leadership and strategic guidance.
Biotech Innovation through Strategic Regulatory Support
who we are
Expert. Strategic. Hands-On. Experienced. Successful.
Who Should Reach Out
- Universities, academic centers, or early-stage innovation teams with a strong idea and domain expertise but uncertainty around next steps toward approval
- Private companies with uncertainties about steps to approval or commercialization
- Public companies navigating the next steps to commercialization
- Venture firms, family offices, or private equity firms seeking diligence on product or strategy
We empower early-stage biotech, medical device, and diagnostic companies, as well as academic researchers and innovators, to advance their breakthroughs from discovery to regulatory approval and commercial success.
Since our founding 27 years ago, Broom Street Associates has brought together industry veterans with more than 150 years of combined experience to provide tailored, hands-on regulatory, clinical, manufacturing, and nonclinical support that adapts to each client’s unique challenges and development stage.
Our approach combines deep industry knowledge with practical, responsive guidance across complex regulatory pathways, clinical development, CMC/manufacturing, toxicology, and strategic diligence. Our cost-effective approach allows our clients to maintain focus on scientific innovation while we help navigate the intricate requirements for INDs, IDEs, clinical holds, and global regulatory interactions. Flexible and collaborative, we partner closely with academic centers, startups, and emerging companies — delivering the strategic clarity and operational support needed to move confidently from benchtop to bedside.